[ad_1] Peter Schmid, FRCP, MD, PhD The combination atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) showed a benefit of 2.5 months in terms of progression-free survival (PFS) compared with nab-paclitaxel alone in patients with …
Read More »Atezolizumab and Nab-Paclitaxel from Frontline Demonstrate the Benefits of PFS in PD-L1 + mTNBC
